The BMJ is an international peer reviewed medical journal and a fully “online first” publication. The BMJ’s vision is to be the world’s most influential and widely read medical journal. Our mission is to lead the debate on health and to engage, inform, and stimulate doctors, researchers, and other health professionals in ways that will improve outcomes for patients. We aim to help doctors to make better decisions.
Rivaroxaban for Reducing Vascular Event Risks after Limb Revascularization for Peripheral Artery Disease – The VOYAGER PAD Trial with Dr. Marc Bonaca
Manage episode 263161086 series 2295711
In today’s podcast we are joined by Dr. Marc Bonaca to discuss the findings of the recent VOYAGER PAD trial and the use of low-dose rivaroxaban in peripheral artery disease after revascularization.